RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

Go back to RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
REDHILL BIO SP ADS (NASDAQ: RDHL) Delayed: 0.42 -0.04 (8.7%)
Previous Close $0.46    52 Week High $16.54 
Open $0.46    52 Week Low $8.10 
Day High $0.47    P/E N/A 
Day Low $0.41    EPS $0.00 
Volume 236,400       

REDHILL BIO SP ADS (NASDAQ: RDHL) Delayed: 0.42 -0.04 (8.7%)
Previous Close $0.46    52 Week High $16.54 
Open $0.46    52 Week Low $8.10 
Day High $0.47    P/E N/A 
Day Low $0.41    EPS $0.00 
Volume 236,400